Product information and disease description / Product description / Product information
Generic, brand name and therapeutic class of product
5 evidence topics · 4 sources
Nonproprietary name, former development code, and therapeutic class
Substance names and development codes in the FDA substance registration record
Development code FTP-637 in the first-in-human registry record
Company names and acquisition of envudeucitinib
“Alumis was incubated by Foresite Labs and incorporated on January 29, 2021, as a Delaware corporation under the name FL2021-001, Inc. FL2021-001, Inc.’s name was changed to Esker Therapeutics, Inc. in March 2021, and to Alumis Inc. in January 2022.” (opens the source at this quote in a new tab)
“For example, we were founded in January 2021, and subsequently acquired envu via a stock purchase of FronThera U.S. Holdings, Inc. and its wholly owned subsidiary, FronThera U.S. Pharmaceuticals LLC.” (opens the source at this quote in a new tab)
“On March 5, 2021, we entered into the FronThera Acquisition, and the transaction was accounted for as an asset acquisition.” (opens the source at this quote in a new tab)
“Additionally, we consummated the ACELYRIN Merger in May 2025 and acquired lonigutamab.” (opens the source at this quote in a new tab)